Loading cancer entity…
Loading cancer entity…
Clinical trials
4,033 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (699)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06453902 | TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients | recruiting | Phase 2 | 40 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06827899 | Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML | recruiting | Phase 2 | 66 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT05881265 | Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia | recruiting | Phase 2 | 30 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT05601726 | First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients(ODYSSEY) | recruiting | Phase 1 / Phase 2 | 36 | Advanced BioDesignINDUSTRY | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06783478 | NK Cell Infusion for Remission Consolidation in AML: A Phase II Trial(NKLMA) | not yet recruiting | Phase 2 | 98 | Hospital de Clinicas de Porto AlegreOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06783790 | Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT | recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06754540 | Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention. | not yet recruiting | Phase 2 | 51 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Jan 17, 2025 | clinicaltrials |
| NCT06765915 | Avapritinib Maintenance for AML With KIT Mutations | not yet recruiting | Phase 2 | 47 | Ruijin HospitalOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06765928 | Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT | not yet recruiting | Phase 2 | 73 | Ruijin HospitalOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT04476199 | Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT | active not recruiting | Phase 2 | 100 | Gruppo Italiano Trapianto di Midollo OsseoOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT04160546 | Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP)(ResToP) | active not recruiting | Phase 2 | 80 | Fundacion CRIS de Investigación para Vencer el CáncerOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT06741722 | Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML | recruiting | Phase 2 | 20 | Beijing 302 HospitalOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06746519 | BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 135 | Chen SuningOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT04147533 | Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia(HALF) | active not recruiting | Phase 2 | 150 | Masaryk UniversityOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06420063 | Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML(BAH244) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT04763928 | Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax(ENABLE) | active not recruiting | Phase 2 | 101 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06024031 | NAC for Promoting Hematopoietic Recovery in Patients With Acute Myeloid Leukemia After Chemotherapy | active not recruiting | Phase 2 | 30 | Peking University People's HospitalOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT05503134 | Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML(KARMA) | recruiting | Phase 1 / Phase 2 | 20 | Nationwide Children's HospitalOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT03603795 | Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy(EPAG2015) | active not recruiting | Phase 2 | 110 | French Innovative Leukemia OrganisationOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT03609060 | Dexamethasone Added to Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML)(DEXAML-02) | active not recruiting | Phase 2 | 120 | French Innovative Leukemia OrganisationOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT06652685 | Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia | not yet recruiting | Phase 2 | 218 | Ruijin HospitalOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT06598384 | VA as Maintenance Therapy Post Allo-HSCT in MDS and AML | not yet recruiting | Phase 2 | 40 | Navy General Hospital, BeijingOTHER | 0 | Oct 1, 2024 | clinicaltrials |
| NCT06621199 | Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML | recruiting | Phase 2 | 42 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04097470 | Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients(HO155) | active not recruiting | Phase 2 | 140 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 4 | Sep 19, 2024 | clinicaltrials |
| NCT06598969 | TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia(TMLI-MA) | not yet recruiting | Phase 2 | 58 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06602323 | TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia.(TMLI-RI) | not yet recruiting | Phase 2 | 34 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06475820 | Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis | active not recruiting | Phase 2 / Phase 3 | 150 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT06221683 | Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML(GMCAII) | recruiting | Phase 2 | 500 | Children's Hospital of Soochow UniversityOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06316960 | Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation | recruiting | Phase 2 | 50 | Children's Hospital of Soochow UniversityOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06470841 | CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML | not yet recruiting | Phase 2 | 85 | Navy General Hospital, BeijingOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06544109 | Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients(Ven APL) | enrolling by invitation | Phase 2 / Phase 3 | 98 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06536959 | VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS | recruiting | Phase 2 | 67 | Beijing 302 HospitalOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06537843 | Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia(VenCM) | recruiting | Phase 2 | 100 | Hospital Municipal São JoséOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06532084 | Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen(SoraGVL) | recruiting | Phase 2 | 88 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06508099 | Vitamin A and D Supplementation in Allogeneic HCT(VitaStem) | recruiting | Phase 2 | 220 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT05870475 | Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV(PV) | recruiting | Phase 2 | 94 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT04968015 | Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission(LAMSA2020) | active not recruiting | Phase 2 | 134 | French Innovative Leukemia OrganisationOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06477549 | BeFluBu vs FluBuRux Conditioning in Haploidentical HCT | recruiting | Phase 2 | 220 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT04905810 | Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure | recruiting | Phase 2 | 20 | Brian JonasOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05580861 | Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment(SALMA) | recruiting | Phase 1 / Phase 2 | 64 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT06387420 | A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia | not yet recruiting | Phase 1 / Phase 2 | 180 | AkesoINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT03999723 | Combining Active and Passive DNA Hypomethylation(EVI-3) | recruiting | Phase 2 | 196 | Kirsten GrønbækOTHER | 2 | Apr 17, 2024 | clinicaltrials |
| NCT04793919 | Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia | recruiting | Phase 2 | 89 | Associazione Italiana Ematologia Oncologia PediatricaOTHER | 12 | Apr 15, 2024 | clinicaltrials |
| NCT06206174 | TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies | recruiting | Phase 1 / Phase 2 | 30 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Apr 10, 2024 | clinicaltrials |
| NCT05319249 | Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia(NAKIP-AML) | not yet recruiting | Phase 1 / Phase 2 | 54 | German Cancer Research CenterOTHER | 0 | Apr 5, 2024 | clinicaltrials |
| NCT01686334 | Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission(WIDEA) | active not recruiting | Phase 2 | 130 | Zwi BernemanOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06046313 | Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS | recruiting | Phase 2 | 120 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT06050941 | Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS | not yet recruiting | Phase 2 | 60 | First Affiliated Hospital of Zhejiang UniversityOTHER | 0 | Mar 5, 2024 | clinicaltrials |
| NCT06133556 | Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML | not yet recruiting | Phase 2 | 237 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Nov 15, 2023 | clinicaltrials |
| NCT06125652 | Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Nov 9, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Feb 21, 2025source: clinicaltrials